{
  "query": "What are the latest CAR-T therapies for solid tumors?",
  "response": "CAR-T therapy is challenging in solid tumors due to immunosuppressive microenvironment and antigen heterogeneity. Promising targets include mesothelin (mesothelioma), HER2 (breast/gastric), and GD2 (neuroblastoma). Clinical trials ongoing, but no FDA approvals yet for solid tumors.",
  "attention": {
    "sources": [
      "CAR-T-solid-tumors.pdf",
      "cellular-therapy-review.pdf"
    ],
    "weights": [
      0.55,
      0.45
    ],
    "patterns": [
      "sources:2",
      "outcome:success"
    ]
  },
  "outcome": "success",
  "confidence": 0.84,
  "timestamp": 1760058208798,
  "memory_type": "long-term",
  "id": "fd8ded7e07718c7a5b4944a0e577264c3161c641cf2b32ba413d1c624ae774ea"
}